GlassScriptPhysician profile
Melissa Schade
NPI 1205303302
$860.57
in general payments reported to CMS, 2019-2025
19 companies · $290 in 2025
The $290 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $148 · 2023: $213 · 2024: $209 · 2025: $290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $712.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $712.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $116.71 | 2022-2024 | |
| Novo Nordisk INC | $110.48 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Phathom Pharmaceuticals, INC. | $106.61 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $97.21 | 2022-2024 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $61.96 | 2023-2025 | Farxiga, Airsupra |
| Otsuka America Pharmaceutical, INC. | $50.53 | 2023-2025 | Rexulti |
| Pfizer INC. | $44.44 | 2025 | |
| Exact Sciences Corporation | $33.29 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.62 | 2022-2024 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $29.44 | 2022-2023 | Seglentis |
| Glaxosmithkline, LLC. | $28.24 | 2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Axsome Therapeutics, INC. | $27.48 | 2025 | Auvelity |
| Abbott Laboratories | $23.01 | 2024 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $20.60 | 2023 | Vaxneuvance, M-M-R II, Vaxelis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.28 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $15.82 | 2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.00 | 2025 | Caplyta |
| Alnylam Pharmaceuticals INC. | $14.75 | 2022 | |
| Shield Therapeutics INC | $14.10 | 2023 | Accrufer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Schade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.